DexCom, Inc. vs Pfizer, Inc. — Stock Comparison

DXCM
DexCom, Inc.
$61.35
▲ 3.02%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
DexCom, Inc.
DXCM8.8/10vs 6.5/10

Q·Score Breakdown

8.8
Very Bullish
Overall
6.5
Neutral
8.5
Quality
7.4
9.1
Health
7
8.9
Growth
5.6
9.2
Valuation
6.7
8.4
Sentiment
5.2
DXCM

Consensus analyst target of $83.92 is 37% above current price.

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $83.92 (+36.8%)
24 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

DXCM
PFE
26.3×
Trailing P/E
19.4×
20.1×
Forward P/E
9.4×
19.3%
Profit Margin
12.4%
61.5%
Gross Margin
75.8%
35.6%
ROE
8.9%
15.0%
Revenue Growth
-1.2%
91.9%
Earnings Growth
Beta
0.39
Price / Book
$23.7B
Market Cap
$149.8B
$54 – $90
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →